JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price objective lifted by investment analysts at JPMorgan Chase & Co. from $167.00 to $168.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 16.60% from the stock's current price.

A number of other equities analysts have also recently weighed in on ASND. Oppenheimer decreased their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Stifel Nicolaus raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $170.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 11th. StockNews.com raised Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $193.43.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $1.59 during midday trading on Thursday, hitting $144.08. 551,280 shares of the company's stock traded hands, compared to its average volume of 433,669. The firm's fifty day moving average price is $132.41 and its two-hundred day moving average price is $132.34. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The company has a market cap of $8.74 billion, a PE ratio of -17.83 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -7.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Large investors have recently made changes to their positions in the business. Signaturefd LLC grew its position in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock worth $102,000 after acquiring an additional 80 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company's stock worth $1,664,000 after buying an additional 4,338 shares during the last quarter. Rice Hall James & Associates LLC increased its holdings in Ascendis Pharma A/S by 5.9% during the 3rd quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company's stock valued at $23,981,000 after purchasing an additional 8,958 shares in the last quarter. Pursue Wealth Partners LLC acquired a new position in Ascendis Pharma A/S during the 3rd quarter worth about $217,000. Finally, Harbor Capital Advisors Inc. increased its holdings in shares of Ascendis Pharma A/S by 67.2% in the third quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company's stock valued at $13,035,000 after purchasing an additional 35,102 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.